Skip to content

A randomized phase II study to evaluate quality of life after total gastrectomy using a linear stapler vs a circular stapler for esophagojejunostomy

A randomized phase II study to evaluate quality of life after total gastrectomy using a linear stapler vs a circular stapler for esophagojejunostomy

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1042180138
Enrollment
50
Registered
2019-03-28
Start date
2016-09-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer Gastric cancer

Interventions

Arm A) Esophagojejunostomy using a circular stapler. Arm B) Esophagojejunostomy using a linear stapler.
D000713

Sponsors

Terashima Masanori
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histologically proven adenocarcinoma of the stomach 2. A total gastrectomy with curative intention is planned for gastric cancer located in the upper third of the stomach. 3. cStage I-III 4. No esophageal invasion >3 cm 5. No gastric stump cancer 6. 20-year-old or older 7. Eastern cooperative oncology group performance status is 0 or 1. 8. No previous chemotherapy or radiation therapy, including those for other cancers 9. Body mass index is less than 30. 10. Fulfills all of the following conditions WBC>3,000/mm3 Plt>100,000/mm3 AST<100IU/L ALT<100IU/L T.Bil<2.0g.dl Cre<1.5mg/dl 11. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Other active cancer 2. Active infectious disease 3. Possibly pregnant, or breast feeding woman 4. Psychiatric disorder 5. Receiving steroids 6. Acute myocardial infarction within 6 months or unstable angina 7. Uncontrolled hypertension 8. Uncontrolled diabetes mellitus and receiving insulin treatment 9. Pulmonary disease requiring continuous oxygen therapy

Design outcomes

Primary

MeasureTime frame
Postgastrectomy syndrome at 12 months after operation (Complaint will be evaluated by EORTC QLQ-STO22)

Secondary

MeasureTime frame
1) EORTC QLQ-C30, EORTC QLQ-STO22 score (excepting the items of eating restriction), 2) incidence of adverse events , 3) operation time (time for anastomosis), 4) amount of bleeding during surgery, 5) body weight loss after surgery, 6) trend of serum albumin level after surgery, 7) completion rate of adjuvant chemotherapy, 8) overall survival

Contacts

Public ContactKenichiro Furukawa

Shizuoka Cancer Center

ke.furukawa@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026